Loss of profilin 2 contributes to enhanced epithelial-mesenchymal transition and metastasis of colorectal cancer

Zhang,Hui; Yang,Weiqiang; Yan,Jinlong; Zhou,Kaiping; Wan,Boshun; Shi,Peidong; Chen,Yueyu; He,Songbing; Li,Dechun

doi:10.3892/ijo.2018.4475

Loss of profilin 2 contributes to enhanced epithelial-mesenchymal transition and metastasis of colorectal cancer

Authors:
- Hui Zhang
- Weiqiang Yang
- Jinlong Yan
- Kaiping Zhou
- Boshun Wan
- Peidong Shi
- Yueyu Chen
- Songbing He
- Dechun Li
View Affiliations

Affiliations: Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of General Surgery, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai 201800, P.R. China
Published online on: July 9, 2018 https://doi.org/10.3892/ijo.2018.4475
Pages: 1118-1128
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Profilin 2 (PFN2) functions as an actin cytoskeleton regulator and serves an important role in cell motility. However, a role for PFN2 in the progression of colorectal cancer (CRC), particularly in metastasis, has yet to be clarified. The aim of the present study was to investigate whether PFN2 served specific roles in the progression of human CRC. The results demonstrated that PFN2 was differentially expressed in CRC tissues and cell lines by reverse transcription-quantitative polymerase chain reaction and western blotting. PFN2 expression was also negatively associated with the degree of tumor metastasis. Low PFN2 expression in CRC cells was related with enhanced epithelial-mesenchymal transition (EMT) and, in turn, may increase migratory capabilities. Overexpression of PFN2 in CRC cell lines with a low level of endogenous PFN2 inhibited the EMT process, as well as the associated migration; in addition, myosin light chain (MLC) phosphorylation was upregulated. Inhibition of MLC phosphorylation attenuated the inhibition of EMT and cell migratory abilities induced by PFN2 overexpression in CRC cell lines, the results suggested that PFN2 may suppress cancer EMT and the subsequent metastasis by regulating cytoskeletal reorganization. These results demonstrated that PFN2 may serve a suppressive role in the metastasis of CRC and therefore may provide a new potential target for cancer therapeutics.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Iseki Y, Shibutani M, Maeda K, Nagahara H, Ohtani H, Sugano K, Ikeya T, Muguruma K, Tanaka H, Toyokawa T, et al: Impact of the preoperative controlling nutritional status (CONUT) score on the survival after curative surgery for colorectal cancer. PLoS One. 10:e01324882015. View Article : Google Scholar : PubMed/NCBI
3	Liu H, Ren G, Wang T, Chen Y, Gong C, Bai Y, Wang B, Qi H, Shen J, Zhu L, et al: Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition. Carcinogenesis. 36:459–468. 2015. View Article : Google Scholar : PubMed/NCBI
4	Grünert S, Jechlinger M and Beug H: Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol. 4:657–665. 2003. View Article : Google Scholar : PubMed/NCBI
5	Yilmaz M and Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
6	König K, Meder L, Kröger C, Diehl L, Florin A, Rommerscheidt-Fuss U, Kahl P, Wardelmann E, Magin TM, Buettner R, et al: Loss of the keratin cytoskeleton is not sufficient to induce epithelial mesenchymal transition in a novel KRAS driven sporadic lung cancer mouse model. PLoS One. 8:e579962013. View Article : Google Scholar : PubMed/NCBI
7	Jockusch BM, Murk K and Rothkegel M: The profile of profilins. Rev Physiol Biochem Pharmacol. 159:131–149. 2007.PubMed/NCBI
8	Witke W, Podtelejnikov AV, Di Nardo A, Sutherland JD, Gurniak CB, Dotti C and Mann M: In mouse brain profilin I and profilin II associate with regulators of the endocytic pathway and actin assembly; EMBO J. 17:967–976. 1998. View Article : Google Scholar : PubMed/NCBI
9	Ma CY, Zhang CP, Zhong LP, Pan HY, Chen WT, Wang LZ, Andrew OW, Ji T and Han W: Decreased expression of profilin 2 in oral squamous cell carcinoma and its clinicopathological implications. Oncol Rep. 26:813–823. 2011.PubMed/NCBI
10	Greene FL: Current TNM staging of colorectal cancer. Lancet Oncol. 8:572–573. 2007. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
12	Castosa R, Martinez-Iglesias O, Roca-Lema D, Casas-Pais A, Díaz-Díaz A, Iglesias P, Santamarina I, Graña B, Calvo L, Valladares-Ayerbes M, et al: Hakai overexpression effectively induces tumour progression and metastasis in vivo. Sci Rep. 8:3466–3475. 2018. View Article : Google Scholar : PubMed/NCBI
13	Findlay VJ, Wang C, Watson DK and Camp ER: Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: Insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther. 21:181–187. 2014. View Article : Google Scholar : PubMed/NCBI
14	Ferron F, Rebowski G, Lee SH and Dominguez R: Structural basis for the recruitment of profilin-actin complexes during filament elongation by Ena/VASP. EMBO J. 26:4597–4606. 2007. View Article : Google Scholar : PubMed/NCBI
15	Mouneimne G, Hansen SD, Selfors LM, Petrak L, Hickey MM, Gallegos LL, Simpson KJ, Lim J, Gertler FB, Hartwig JH, et al: Differential remodeling of actin cytoskeleton architecture by profilin isoforms leads to distinct effects on cell migration and invasion. Cancer Cell. 22:615–630. 2012. View Article : Google Scholar : PubMed/NCBI
16	Takebe T, Enomura M, Yoshizawa E, Kimura M, Koike H, Ueno Y, Matsuzaki T, Yamazaki T, Toyohara T, Osafune K, et al: Vascularized and complex organ buds from diverse tissues via mesenchymal cell-driven condensation. Cell Stem Cell. 16:556–565. 2015. View Article : Google Scholar : PubMed/NCBI
17	Kanaan Z, Qadan M, Eichenberger MR and Galandiuk S: The actin-cytoskeleton pathway and its potential role in inflammatory bowel disease-associated human colorectal cancer. Genet Test Mol Biomarkers. 14:347–353. 2010. View Article : Google Scholar : PubMed/NCBI
18	Schlüter K, Jockusch BM and Rothkegel M: Profilins as regulators of actin dynamics. Biochim Biophys Acta. 1359:97–109. 1997. View Article : Google Scholar : PubMed/NCBI
19	Liu J, Wu Y, Wang Q, Liu X, Liao X and Pan J: Bioinformatic analysis of PFN2 dysregulation and its prognostic value in head and neck squamous carcinoma. Future Oncol. 14:449–459. 2018. View Article : Google Scholar : PubMed/NCBI
20	Cui XB, Zhang SM, Xu YX, Dang HW, Liu CX, Wang LH, Yang L, Hu JM, Liang WH, Jiang JF, et al: PFN2, a novel marker of unfavorable prognosis, is a potential therapeutic target involved in esophageal squamous cell carcinoma. J Transl Med. 14:137–152. 2016. View Article : Google Scholar : PubMed/NCBI
21	Yan J, Ma C and Gao Y: MicroRNA-30a-5p suppresses epithelial-mesenchymal transition by targeting profilin-2 in high invasive non-small cell lung cancer cell lines. Oncol Rep. 37:3146–3154. 2017. View Article : Google Scholar : PubMed/NCBI
22	Ding Z and Roy P: Profilin-1 versus profilin-2: Two faces of the same coin. Breast Cancer Res. 15:311–312. 2013. View Article : Google Scholar
23	Cheng YJ, Zhu ZX, Zhou JS, Hu ZQ, Zhang JP, Cai QP and Wang LH: Silencing profilin-1 inhibits gastric cancer progression via integrin β1/focal adhesion kinase pathway modulation. World J Gastroenterol. 21:2323–2335. 2015. View Article : Google Scholar : PubMed/NCBI
24	Karamchandani JR, Gabril MY, Ibrahim R, Scorilas A, Filter E, Finelli A, Lee JY, Ordon M, Pasic M, Romaschin AD, et al: Profilin-1 expression is associated with high grade and stage and decreased disease-free survival in renal cell carcinoma. Hum Pathol. 46:673–680. 2015. View Article : Google Scholar : PubMed/NCBI
25	Coumans JV, Gau D, Poljak A, Wasinger V, Roy P and Moens PD: Profilin-1 overexpression in MDA-MB-231 breast cancer cells is associated with alterations in proteomics biomarkers of cell proliferation, survival, and motility as revealed by global proteomics analyses. OMICS. 18:778–791. 2014. View Article : Google Scholar : PubMed/NCBI
26	Liang JW, Shi ZZ, Shen TY, Che X, Wang Z, Shi SS, Xu X, Cai Y, Zhao P, Wang CF, et al: Identification of genomic alterations in pancreatic cancer using array-based comparative genomic hybridization. PLoS One. 9:e1146162014. View Article : Google Scholar : PubMed/NCBI
27	Alkam D, Feldman EZ, Singh A and Kiaei M: Profilin1 biology and its mutation, actin(g) in disease. Cell Mol Life Sci. 74:967–981. 2017. View Article : Google Scholar :
28	Tang YN, Ding WQ, Guo XJ, Yuan XW, Wang DM and Song JG: Epigenetic regulation of Smad2 and Smad3 by profilin-2 promotes lung cancer growth and metastasis. Nat Commun. 6:8230–8239. 2015. View Article : Google Scholar : PubMed/NCBI
29	Tsai JH and Yang J: Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013. View Article : Google Scholar : PubMed/NCBI
30	Savagner P: Epithelial-mesenchymal transitions: From cell plasticity to concept elasticity. Curr Top Dev Biol. 112:273–300. 2015. View Article : Google Scholar : PubMed/NCBI
31	Medici D, Hay ED and Olsen BR: Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. Mol Biol Cell. 19:4875–4887. 2008. View Article : Google Scholar : PubMed/NCBI
32	Qiao Y, Chen J, Lim YB, Finch-Edmondson ML, Seshachalam VP, Qin L, Jiang T, Low BC, Singh H, Lim CT, et al: YAP regulates actin dynamics through ARHGAP29 and promotes metastasis. Cell Reports. 19:1495–1502. 2017. View Article : Google Scholar : PubMed/NCBI
33	Wieczorek K, Wiktorska M, Sacewicz-Hofman I, Boncela J, Lewiński A, Kowalska MA and Niewiarowska J: Filamin A upregulation correlates with Snail-induced epithelial to mesenchymal transition (EMT) and cell adhesion but its inhibition increases the migration of colon adenocarcinoma HT29 cells. Exp Cell Res. 359:163–170. 2017. View Article : Google Scholar : PubMed/NCBI
34	Izdebska M, Gagat M and Grzanka A: Overexpression of lamin B1 induces mitotic catastrophe in colon cancer LoVo cells and is associated with worse clinical outcomes. Int J Oncol. 52:89–102. 2018.